🇺🇸 FDA

Intelligence · Clinical Pipeline

CORCEPT THERAPEUTICS Pipeline

All ClinicalTrials.gov programs at CORCEPT THERAPEUTICS — phase, modality, and trial IDs.

Programs
20

Quick answer

CORCEPT THERAPEUTICS has 20 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. CORT113176, CORT113176, Placebo to Dazucorilant softgel capsule

    CORCEPT THERAPEUTICS INC

    Amyotrophic Lateral Sclerosis

    phase 2 small molecule active

    1 trial

  2. CORT125134

    CORCEPT THERAPEUTICS INC

    Cushing's Syndrome

    phase 2 small molecule completed

    1 trial

  3. CORT125134, PACLITAXEL ALBUMIN-BOUND, BEVACIZUMAB, relacorilant

    CORCEPT THERAPEUTICS INC

    Gynecological Cancers

    phase 2 small molecule active

    1 trial

  4. Dazucorilant 300 mg

    CORCEPT THERAPEUTICS INC

    Amyotrophic Lateral Sclerosis

    phase 2 small molecule active

    1 trial

  5. Enzalutamide

    CORCEPT THERAPEUTICS INC

    Metastatic Breast Cancer

    phase 2 small molecule active

    1 trial

  6. Exicorilant

    CORCEPT THERAPEUTICS INC

    Metastatic Castration-Resistant Prostate Cancer

    phase 2 small molecule terminated

    1 trial

  7. Mifepristone

    CORCEPT THERAPEUTICS INC

    Weight-Gain Prevention

    phase 2 small molecule completed

    1 trial

  8. Mifepristone

    CORCEPT THERAPEUTICS INC

    Alzheimer's Disease

    phase 2 small molecule terminated

    1 trial

  9. Mifepristone

    CORCEPT THERAPEUTICS INC

    Central Adrenal Insufficiency

    phase 2 small molecule terminated

    1 trial

  10. Mifepristone

    CORCEPT THERAPEUTICS INC

    Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule terminated

    1 trial

  11. Mifepristone 1200 mg daily

    CORCEPT THERAPEUTICS INC

    Treatment-resistant PTSD

    phase 2 small molecule active

    1 trial

  12. Miricorilant

    CORCEPT THERAPEUTICS INC

    Antipsychotic-induced Weight Gain (AIWG)

    phase 2 small molecule completed

    1 trial

  13. Miricorilant

    CORCEPT THERAPEUTICS INC

    Nonalcoholic Steatohepatitis (NASH)

    phase 2 small molecule active

    3 trials

  14. Miricorilant (Cohort A)

    CORCEPT THERAPEUTICS INC

    Nonalcoholic Steatohepatitis (NASH)

    phase 2 small molecule active

    1 trial

  15. Miricorlilant

    CORCEPT THERAPEUTICS INC

    Antipsychotic-induced Weight Gain (AIWG)

    phase 2 small molecule completed

    1 trial

  16. Nenocorilant 200 mg

    CORCEPT THERAPEUTICS INC

    Neoplasms

    phase 2 small molecule active

    1 trial

  17. Relacorilant

    CORCEPT THERAPEUTICS INC

    Recurrent Ovarian Cancer

    phase 2 small molecule completed

    1 trial

  18. Relacorilant 150 mg once daily (QD)

    CORCEPT THERAPEUTICS INC

    Adenocarcinoma

    phase 2 small molecule active

    1 trial

  19. Relacorilant 150 mg once daily (QD)

    CORCEPT THERAPEUTICS INC

    Ovarian Cancer

    phase 2 small molecule active

    1 trial

  20. Relacorilant with nab-paclitaxel

    CORCEPT THERAPEUTICS INC

    Solid Tumors

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many pipeline programs does CORCEPT THERAPEUTICS have?

20 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.